logo-loader
viewNyrada

Nyrada Inc developing exciting drugs for cholesterol and 'first-ever treatment' for brain injury

Nyrada Inc's (ASX:NYR) James Bonnar tells Proactive's Andrew Scott they listed on the ASX in January this year and are working on two really exciting drugs - the first is what he believes to be the first-ever treatment for brain injury and the second is a cholesterol-lowering drug. He says what makes their brain injury candidate unique and sets it apart from what is available currently is that it's a small molecule drug which means it's cheap to produce and can be formulated in a pill. Bonnar says its cholesterol lowering drug will get into the clinic late next year and will be shortly followed by their brain injury drug. He says they're both addressing very large markets - each in the area of US$20bn

Quick facts: Nyrada

Price: 0.195 AUD

ASX:NYR
Market: ASX
Market Cap: $21.33 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

7 hours, 26 minutes ago

2 min read